In this paper, we identified CD271 as a new mechanism of acquired resistance of melanoma cells to BRAFi that involves tumor necrosis factor-alpha (TNFα)/NF-κB pathway activation and sustained CD271 expression. Here, NGFR is linked to melanoma.